medroxyprogesterone acetate has been researched along with Osteoporosis, Postmenopausal in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.57) | 18.7374 |
| 1990's | 19 (33.93) | 18.2507 |
| 2000's | 32 (57.14) | 29.6817 |
| 2010's | 3 (5.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, SH; Choi, YM; Lee, DY; Park, HM; Park, MC; Yoon, BK | 1 |
| Chen, Y; Lin, SQ; Ran, SY; Yu, Q | 1 |
| Chines, AA; Komm, BS; Mirkin, S; Pan, K | 1 |
| Blake, JM; Christilaw, J; Collins, JA; Cooper, J; Fedorkow, DM; Fortier, M; Fortin, C; Jolly, EE; Lalonde, AB; Lemay, A; Maxted, JM; O'Grady, K; O'Grady, T; Reid, RL; Smith, TE; Turek, MA | 1 |
| Romero, M | 1 |
| Keller, PJ; Merki-Feld, GS; Neff, M | 1 |
| Chen, F; de Lignieres, B; Lin, S; Qin, M; Sun, A; Wei, Y; Yu, W; Zhang, Y | 1 |
| Chen, F; Lin, S; Lu, J; Shen, Y; Yu, W; Zhang, L; Zhang, Y | 1 |
| Sagraves, R | 1 |
| Greenspan, SL; Parker, RA; Resnick, NM | 1 |
| Stjernquist, M | 1 |
| Binder, EF; Brown, M; Kohrt, WM; Sinacore, DR; Villareal, DT; Williams, DB; Yarasheski, KE | 1 |
| Altintas, A; Baksu, B; Davas, I; Varolan, A; Yazgan, A; Yoldemir, T | 1 |
| Irahara, M; Takikawa, M; Uemura, H; Yasui, T | 1 |
| Bhagat, CI; Criddle, RA; Dhaliwal, SS; Drury, PJ; Faulkner, DL; Gutteridge, DH; Holzherr, ML; Jamrozik, K; Kent, GN; Price, RI; Prince, RL; Retallack, RW; Stewart, GO; Stuckey, BG; Tran, L; Will, RK | 1 |
| Borakowska, B; Michalewski, K; Radowicki, S; Skórzewska, K; Wierzba, W | 1 |
| Lindsay, R | 2 |
| Gallagher, JC; Kleerekoper, M; Lindsay, R; Pickar, JH | 1 |
| Falbo, A; Lombardi, G; Manguso, F; Mastrantonio, P; Nunziata, V; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F | 1 |
| Gallagher, JC; Haynatzka, V; Knezetic, JA; Rapuri, PB | 1 |
| Gorai, I; Hayashi, K; Ishihara, O; Itoga, S; Iwaoki, Y; Kasuga, Y; Kosha, S; Kurabayashi, T; Makita, K; Mizunuma, H; Mochizuki, Y; Mogi, H; Shintani, M; Shiraki, M; Yasui, T | 1 |
| Albertazzi, P; Bottazzi, M; Steel, SA | 1 |
| Ichikawa, L; LaCroix, AZ; Ott, SM; Scholes, D; Wetmore, CM | 1 |
| Cosman, F; Lindsay, R; Nieves, J; Shen, V | 1 |
| Adashi, EY; Langenberg, P; Udoff, L | 1 |
| Ren, Y; Zhu, G | 1 |
| Cundy, TF; Grey, AB; Reid, IR | 1 |
| Bertinetti, G; Dell'Elce, C; Delzanno, G; Gaudiano, L; Paoletti, R; Ventrella, CA | 1 |
| Biberoğlu, KO; Kandemir, O; Yildiz, A | 1 |
| Byrjalsen, I; Christiansen, C; Haarbo, J | 1 |
| Meiss, F; Ringe, JD | 1 |
| Insua, A; Negri, A; Zanchetta, JR | 1 |
| Cundy, T; Evans, M; Grey, A; Reid, I | 1 |
| Kanis, JA | 1 |
| Alvarez de los Heros, JI; Pérez-Jaraiz, MD; Revilla, M; Rico, H; Villa, LF | 1 |
| Heikkinen, J; Kurttila-Matero, E; Kyllönen, E; Lankinen, KS; Rita, H; Väänänen, HK; Wilén-Rosenqvist, G | 1 |
| Carlson, CS; Jayo, MJ; Register, TC | 1 |
| Harada, A; Hosoi, T; Ikeda, K; Miyauchi, A; Ohta, H; Shiraki, M; Yamada, Y | 1 |
| Clearwater, JM; Evans, MC; Grey, AB; Horne, A; Orr-Walker, BJ; Reid, IR | 1 |
| Heikkinen, J; Kainulainen, P; Timonen, U; Vaheri, R | 1 |
| Alaghband-Zadeh, J; Chow, J; Fox, S; Holland, N; Khastgir, G; Studd, J | 1 |
| Detter, JR; Fowler, SE; Gallagher, JC; Sherman, SS | 1 |
| Groh, KW; Stevermer, JJ | 1 |
| Lin, S; Sun, A; Wei, Y | 1 |
| Castelo-Branco, C; Figueras, F; Pons, F; Sanjuán, A; Vanrell, JA | 1 |
| Gass, M; Liu, J; Rebar, RW | 1 |
| Bigler, JM; Burckhardt, P; Landry, M; Pache, T; Renteria, S; Thiébaud, D; Welti, HJ | 1 |
| Barrett-Connor, E; Espeland, M; Greendale, GA; Marcus, R; Slone, S | 1 |
| Cornish, J; Cundy, T; Reid, IR; Roberts, H | 1 |
| Armamento-Villareal, R; Civitelli, R; Cohen, S; Dotson, M; Hauser, J; Hildebolt, CF; Kardaris, EE; Lewandowski, N; Muckerman, J; Pilgram, TK; Yokoyama-Crothers, N | 1 |
| Barbacini, P; Brincat, M; Crosignani, PG; Maini, MC; Marri, R; Meschia, M | 1 |
| Caplan, RH; Hodgson, SF; Judd, HL; Kotowicz, MA; Lane, AW; Lufkin, EG; O'Fallon, WM; Riggs, BL; Wahner, HW | 1 |
| Heikkinen, J; Kurttila-Matero, E; Kyllönen, E; Takala, T; Väänänen, HK; Vuori, J | 1 |
| Christiansen, C; Marslew, U; Riis, BJ | 1 |
| Dören, M; Montag, M; Schneider, HP | 1 |
5 review(s) available for medroxyprogesterone acetate and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Bioidentical hormone replacement therapy. Customizing care for perimenopausal and menopausal women.
Topics: Chemistry, Pharmaceutical; Climacteric; Drug Combinations; Drug Compounding; Drug Monitoring; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Estrogens, Non-Steroidal; Female; Humans; Isoflavones; Medroxyprogesterone Acetate; Menopause; Osteoporosis, Postmenopausal; Patient Care Planning; Phytoestrogens; Plant Preparations; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators | 2002 |
Hormone replacement therapy in postmenopausal women.
Topics: Administration, Cutaneous; Atrophy; Breast Neoplasms; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Medroxyprogesterone Acetate; Osteoporosis, Postmenopausal; Postmenopause; Randomized Controlled Trials as Topic; Risk; Vagina | 2003 |
Hormones and bone health in postmenopausal women.
Topics: Aged; Bone and Bones; Bone Density; Clinical Trials as Topic; Dose-Response Relationship, Drug; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Fractures, Bone; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Women's Health | 2004 |
Combined continuous hormone replacement therapy: a critical review.
Topics: Bone Density; Climacteric; Endometrium; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Lipoproteins; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Postmenopause | 1995 |
Estrogens in prevention and treatment of osteoporosis.
Topics: Aged; Drug Combinations; Estrogen Replacement Therapy; Estrogens; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy | 1989 |
33 trial(s) available for medroxyprogesterone acetate and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial.
Topics: Aged; Alendronate; Amino Acids; Asian People; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Humans; Lumbar Vertebrae; Mastodynia; Medroxyprogesterone Acetate; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Republic of Korea | 2017 |
Prevention of postmenopausal osteoporosis in Chinese women: a 5-year, double-blind, randomized, parallel placebo-controlled study.
Topics: Adult; Asian People; Bone Density; Breast Neoplasms; China; Double-Blind Method; Estradiol; Estrogen Replacement Therapy; Female; Femur Neck; Glycolipids; Humans; Lumbar Vertebrae; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Pelvic Bones; Placebos; Postmenopause; Treatment Outcome | 2017 |
Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Endometrial Hyperplasia; Estrogens, Conjugated (USP); Female; Humans; Indoles; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Postmenopause; Selective Estrogen Receptor Modulators | 2013 |
Percutaneous estrogen in prevention of early postmenopausal bone loss in Chinese women.
Topics: Administration, Cutaneous; Adult; Bone Density; Estradiol; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal | 2002 |
[Prevention of bone loss by estradiol valerate combined with medroxyprogesterone acetate among postmenopausal women with osteopenia].
Topics: Adult; Bone Density; Bone Diseases, Metabolic; Drug Therapy, Combination; Estradiol; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Progesterone Congeners | 2002 |
Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Double-Blind Method; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Osteoporosis, Postmenopausal; Progesterone Congeners | 2003 |
Effects of exercise training added to ongoing hormone replacement therapy on bone mineral density in frail elderly women.
Topics: Aged; Aged, 80 and over; Body Composition; Bone Density; Combined Modality Therapy; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Exercise Therapy; Female; Fractures, Bone; Frail Elderly; Humans; Medroxyprogesterone Acetate; Osteoporosis, Postmenopausal; Progesterone Congeners; Prospective Studies | 2003 |
Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women.
Topics: Absorptiometry, Photon; Administration, Cutaneous; Administration, Oral; Alendronate; Bone Density; Calcium; Drug Administration Schedule; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Progesterone Congeners | 2003 |
A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.
Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone Density; Calcitriol; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Estrone; Female; Hip Joint; Humans; Hydroxyproline; Medroxyprogesterone Acetate; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Quality of Life; Severity of Illness Index; Single-Blind Method; Spinal Fractures; Treatment Outcome | 2003 |
[Effect and tolerability of sequential administration of estradiol valerate and medroxyprogesterone acetate on menopausal symptoms, hormonal profile and biochemical markers in climacteric women].
Topics: Aged; Biomarkers; Blood Coagulation Factors; Bone Density; Climacteric; Dose-Response Relationship, Drug; Drug Administration Schedule; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Follicle Stimulating Hormone; Humans; Lipids; Male; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Time Factors; Treatment Outcome | 2004 |
Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
Topics: Adult; Aged; Biomarkers; Bone Density; Collagen; Collagen Type I; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Hip Joint; Humans; Lumbar Vertebrae; Medroxyprogesterone Acetate; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides | 2005 |
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Drug Combinations; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Genotype; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Receptors, Calcitriol; Selective Estrogen Receptor Modulators; Treatment Outcome | 2005 |
Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen.
Topics: Aged; Analysis of Variance; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcitriol; Diet Records; Double-Blind Method; Estrogen Receptor alpha; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Longitudinal Studies; Medroxyprogesterone Acetate; Osteoporosis, Postmenopausal; Polymorphism, Genetic | 2006 |
Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss.
Topics: Absorptiometry, Photon; Aged; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Hydroxycholecalciferols; Lumbar Vertebrae; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies | 2006 |
Association between caffeine intake and bone mass among young women: potential effect modification by depot medroxyprogesterone acetate use.
Topics: Absorptiometry, Photon; Adolescent; Adult; Bone Density; Caffeine; Central Nervous System Stimulants; Contraceptive Agents, Female; Female; Fractures, Bone; Humans; Longitudinal Studies; Medroxyprogesterone Acetate; Osteoporosis, Postmenopausal; Treatment Outcome | 2008 |
Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Body Height; Body Weight; Bone Density; Bone Development; Bone Resorption; Calcitriol; Cross-Sectional Studies; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Femur Neck; Humans; Lumbar Vertebrae; Medroxyprogesterone Acetate; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphorus | 1995 |
[The effects of progestin on the bone metabolism in postmenopausal women].
Topics: Bone and Bones; Bone Density; Drug Therapy, Combination; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Quinestrol | 1995 |
[Dihydrogesterone vs. medroxyprogesterone acetate in association with transdermal estradiol in postmenopausal substitution treatment].
Topics: Administration, Cutaneous; Bone Density; Drug Therapy, Combination; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal | 1994 |
Role of cigarette smoking on the postmenopausal endometrium during sequential estrogen and progestogen therapy.
Topics: Desogestrel; Endometrium; Estradiol; Estradiol Dehydrogenases; Estrogen Replacement Therapy; Female; Glycodelin; Glycoproteins; Humans; Isocitrate Dehydrogenase; Levonorgestrel; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Pregnancy Proteins; Smoking | 1993 |
[The avoidance of early postmenopausal bone substance losses by transdermal estrogen substitution].
Topics: Absorptiometry, Photon; Administration, Cutaneous; Administration, Oral; Bone Density; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Time Factors | 1993 |
Prophylaxis of osteoporosis with calcium, estrogens and/or eelcatonin: comparative longitudinal study of bone mass.
Topics: Absorptiometry, Photon; Bone Density; Calcitonin; Calcium; Estradiol; Estrogen Replacement Therapy; Female; Humans; Longitudinal Studies; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal | 1996 |
HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women.
Topics: Bone Density; Cholesterol; Cholesterol, LDL; Climacteric; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Exercise Therapy; Female; Femur; Humans; Isometric Contraction; Lipid Metabolism; Lipids; Lumbar Vertebrae; Medroxyprogesterone Acetate; Menopause; Middle Aged; Muscle Contraction; Muscle, Skeletal; Osteoporosis, Postmenopausal; Placebos; Postmenopause; Progesterone Congeners; Prospective Studies | 1997 |
Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women.
Topics: Absorptiometry, Photon; Aged; Body Mass Index; Bone Density; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Hormone Replacement Therapy; Humans; Hyperparathyroidism; Medroxyprogesterone Acetate; Osteoporosis, Postmenopausal; Postmenopause; Progesterone Congeners; Treatment Outcome | 2000 |
Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens.
Topics: Aged; Analysis of Variance; Bone Density; Double-Blind Method; Drug Combinations; Endometrium; Estradiol; Estradiol Congeners; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Progesterone Congeners; Single-Blind Method; Treatment Outcome | 2000 |
Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Topics: Absorptiometry, Photon; Aged; Bone Density; Calcifediol; Calcitriol; Calcium; Calcium, Dietary; Double-Blind Method; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Femur; Humans; Hysterectomy; Medroxyprogesterone Acetate; Osteocalcin; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Placebos; Progesterone Congeners; Spine; Time Factors | 2001 |
Effect of continuous and sequential oral estrogen-progestogen replacement regimens on postmenopausal bone loss: a 2-year prospective study.
Topics: Absorptiometry, Photon; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Patient Dropouts; Prospective Studies | 2001 |
A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Animals; Bone Density; Calcium; Creatinine; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Femur; Horses; Humans; Hydroxyproline; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Lumbar Vertebrae; Medroxyprogesterone Acetate; Norpregnenes; Osteocalcin; Osteoporosis, Postmenopausal | 1998 |
Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study.
Topics: Bone Density; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Progesterone Congeners; Time Factors; Withholding Treatment | 2002 |
Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial.
Topics: Absorptiometry, Photon; Adult; Aged; Alveolar Bone Loss; Bone Density; Double-Blind Method; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Femur; Humans; Lumbar Vertebrae; Medroxyprogesterone Acetate; Middle Aged; Multivariate Analysis; Osteoporosis, Postmenopausal | 2002 |
Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women.
Topics: Absorptiometry, Photon; Analysis of Variance; Bone Density; Calcitonin; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal | 1992 |
Treatment of postmenopausal osteoporosis with transdermal estrogen.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Bone Density; Double-Blind Method; Drug Therapy, Combination; Estradiol; Estrone; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Spinal Fractures | 1992 |
Desogestrel in hormone replacement therapy: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.
Topics: Absorptiometry, Photon; Bone Density; Calcium; Climacteric; Desogestrel; Drug Therapy, Combination; Estradiol; Female; Humans; Lipids; Medroxyprogesterone; Medroxyprogesterone Acetate; Menstruation; Middle Aged; Norpregnenes; Osteoporosis, Postmenopausal; Progesterone Congeners | 1991 |
[Prospective perimenopausal estrogen-progestin substitution therapies for the prevention of osteoporosis].
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Estradiol; Estriol; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; Norethindrone Acetate; Osteoporosis, Postmenopausal; Prospective Studies | 1989 |
18 other study(ies) available for medroxyprogesterone acetate and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
The SOGC statement on the WHI report on estrogen and progestin use in postmenopausal women.
Topics: Aged; Breast Neoplasms; Cardiovascular Diseases; Drug Combinations; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Evidence-Based Medicine; Female; Humans; Informed Consent; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Patient Education as Topic; Patient Selection; Postmenopause; Risk; Risk Factors; Women's Health | 2002 |
A 2-year prospective study on the effects of depot medroxyprogesterone acetate on bone mass-response to estrogen and calcium therapy in individual users.
Topics: Adult; Bone Density; Calcium; Contraceptive Agents, Female; Delayed-Action Preparations; Dietary Supplements; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Tomography, X-Ray Computed | 2003 |
Evaluating therapeutic modalities for prevention and treatment of postmenopausal osteoporosis.
Topics: Dietary Supplements; Estrogens; Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; National Institutes of Health (U.S.); Osteoporosis, Postmenopausal; Progesterone Congeners; United States; Women's Health | 2003 |
[After the early termination of the Women's Health Initiative study. New American recommendations for postmenopausal hormone therapy].
Topics: Aged; Breast Neoplasms; Coronary Disease; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Practice Guidelines as Topic; Progesterone Congeners; Randomized Controlled Trials as Topic; Risk Factors; Women's Health | 2003 |
Bone mineral density and depot medroxyprogesterone acetate.
Topics: Adult; Body Mass Index; Bone Density; Calcium, Dietary; Contraceptives, Oral, Combined; Cross-Sectional Studies; Delayed-Action Preparations; Female; Femur Neck; Fractures, Bone; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Risk; Spine | 2006 |
Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Female; Femur; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Spine | 1994 |
Bone mineral density in Turkish postmenopausal women.
Topics: Adult; Bone Density; Estrogens; Female; Humans; Medroxyprogesterone Acetate; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Parity; Prospective Studies; Reference Values; Spine; Turkey | 1993 |
[Effects of estrogen therapy on bone mass in postmenopausal women with osteopenia].
Topics: Absorptiometry, Photon; Aged; Analysis of Variance; Bone Density; Calcium, Dietary; Estradiol; Estrogen Replacement Therapy; Female; Femur Neck; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Spine | 1995 |
Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Humans; Hysterectomy; Lumbar Vertebrae; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal | 1996 |
Medroxyprogesterone and bone mineral density response to oestrogen.
Topics: Aged; Bone Density; Drug Synergism; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Humans; Hysterectomy; Lumbar Vertebrae; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Time Factors | 1996 |
Effects on bone of oral hormone replacement therapy initiated 2 years after ovariectomy in young adult monkeys.
Topics: Absorptiometry, Photon; Animals; Biomarkers; Bone Density; Disease Models, Animal; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Lumbar Vertebrae; Macaca fascicularis; Medroxyprogesterone Acetate; Osteoporosis, Postmenopausal; Ovariectomy; Progesterone Congeners; Treatment Outcome | 1998 |
Association of transforming growth factor beta1 genotype with therapeutic response to active vitamin D for postmenopausal osteoporosis.
Topics: Aged; Amino Acid Substitution; Bone Density; Bone Resorption; Calcitriol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Exons; Female; Gene Frequency; Genotype; Humans; Hydroxycholecalciferols; Japan; Medroxyprogesterone Acetate; Middle Aged; Osteoblasts; Osteoporosis, Postmenopausal; Ovariectomy; Point Mutation; Protein Sorting Signals; Transforming Growth Factor beta; Treatment Outcome | 2000 |
Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study.
Topics: Administration, Oral; Aged; Bone and Bones; Bone Density; Drug Implants; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Female; Humans; Longitudinal Studies; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal | 2001 |
Does estrogen/progestin therapy in post-menopausal women decrease their risk of fracture?
Topics: Age Factors; Aged; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Evidence-Based Medicine; Female; Fractures, Bone; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Progesterone Congeners; Risk Factors; Time Factors; Treatment Outcome | 2001 |
[Observation of preventing of bone loss during early postmenopause by percutaneous estradiol in Chinese postmenopausal women].
Topics: Administration, Cutaneous; Aged; Bone Density; Drug Combinations; Estradiol; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause | 2001 |
The effect of low-dose conjugated equine estrogens and cyclic MPA on bone density.
Topics: Bone Density; Calcium Citrate; Dose-Response Relationship, Drug; Drug Administration Schedule; Estrogens, Conjugated (USP); Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Vitamin D | 2002 |
Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception.
Topics: Bone Density; Contraceptive Agents, Female; Delayed-Action Preparations; Estrogen Replacement Therapy; Female; Femur Neck; Humans; Lumbar Vertebrae; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies | 2002 |
Moderate exercise does not enhance the positive effect of estrogen on bone mineral density in postmenopausal women.
Topics: Bone Density; Estradiol; Estradiol Congeners; Exercise; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies | 1991 |